VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis

Cell Research

Volumn 20, Issue 12, 2010, Pages 1319-1331

  Zhang, Luqing ^a   Zhou, Fei ^a   Han, Wencan ^a   Shen, Bin ^a   Luo, Jincai ^b   Shibuya, Masabumi ^c   He, Yulong ^a  

^a NANJING UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

angiogenesis; ligand binding domain; lymphangiogenesis; tyrosine kinase; VEGFR 3

Indexed keywords

LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL; ANIMAL EMBRYO; ANIMAL MODEL; ARTICLE; DIMERIZATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; LYMPHANGIOGENESIS; METABOLISM; MOUSE; PHYSIOLOGY; POINT MUTATION; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION; VASCULARIZATION; YOLK SAC;

ANIMALS; DIMERIZATION; EMBRYO, MAMMALIAN; LIGANDS; LYMPHANGIOGENESIS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MODELS, ANIMAL; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; YOLK SAC;

MUS;

EID: 78649899926     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2010.116     Document Type: Article

References (43)

1. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8:464-478.
2. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005; 438:937-945.
3. De Val S, Black BL. Transcriptional control of endothelial cell development. Dev Cell 2009; 16:180-195.
4. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999; 98:769-778.
5. Oliver G, Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev 2002; 16:773-783.
6. Francois M, Caprini A, Hosking B, et al. Sox18 induces development of the lymphatic vasculature in mice. Nature 2008; 456:643-647.
7. Li X, Claesson-Welsh L, Shibuya M. VEGF receptor signal transduction. Methods Enzymol 2008; 443:261-284.
8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
9. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specifcity and activity of VEGF-C. EMBO J 1997; 16:3898-3911.
10. Stacker SA, Stenvers K, Caesar C, et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 1999; 274:32127-32136.
11. Lamont RE, Childs S. MAPping out arteries and veins. Sci STKE 2006; 2006:pe39.
12. Makinen T, Jussila L, Veikkola T, et al. Inhibition of lymp-hangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7:199-205.
13. Karkkainen MJ, Ferrell RE, Lawrence EC, et al. Missense mutations interfere with VEGFR-3 signalling in primary lym-phoedema. Nat Genet 2000; 25:153-159.
14. He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002; 94:819-825.
15. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995; 92:3566-3570.
16. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154:1381-1390.
17. Clarijs R, Schalkwijk L, Hofmann UB, Ruiter DJ, de Waal RM. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. Cancer Res 2002; 62:7059-7065.
18. Kubo H, Fujiwara T, Jussila L, et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 2000; 96:546-553.
19. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454:656-660.
20. Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998; 282:946-949.
21. Hamada K, Oike Y, Takakura N, et al. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangio-genesis and hematopoiesis. Blood 2000; 96:3793-3800.
22. Haiko P, Makinen T, Keskitalo S, et al. Deletion of vascular endothelial growth factor (VEGF-C) and VEGF-D is not equivalent to VEGFR-3-null in mouse embryos. Mol Cell Biol 2008; 28:4843-4850.
23. Lakso M, Pichel JG, Gorman JR, et al. Effcient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci USA 1996; 93:5860-5865.
24. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specifc receptor for hy-aluronan. J Cell Biol 1999; 144:789-801.
25. Gordon EJ, Gale NW, Harvey NL. Expression of the hyaluro-nan receptor LYVE-1 is not restricted to the lymphatic vascu-lature; LYVE-1 is also expressed on embryonic blood vessels. Dev Dyn 2008; 237:1901-1909.
26. Karkkainen MJ, Saaristo A, Jussila L, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA 2001; 98:12677-12682.
27. Zhang X, Groopman JE, Wang JF. Extracellular matrix regulates endothelial functions through interaction of VEGFR-3 and integrin alpha5beta1. J Cell Physiol 2005; 202:205-214.
28. Karpanen T, Heckman CA, Keskitalo S, et al. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J 2006; 20:1462-1472.
29. Nilsson I, Bahram F, Li X, et al. VEGF receptor 2/-3 het-erodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J 2010; 29:1377-1388.
30. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the frst lymphatic vessels from embryonic veins. Nat Immunol 2004; 5:74-80.
31. He Y, Rajantie I, Pajusola K, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 2005; 65:4739-4746.
32. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is suffcient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95:9349-9354.
33. Dixelius J, Makinen T, Wirzenius M, et al. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic en-dothelial cells regulates tyrosine phosphorylation sites. J Biol Chem 2003; 278:40973-40979.
34. Wang JF, Zhang XF, Groopman JE. Stimulation of beta 1 inte-grin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration. J Biol Chem 2001; 276:41950-41957.
35. Galvagni F, Pennacchini S, Salameh A, et al. Endothelial cell adhesion to the extracellular matrix induces c-Src-dependent VEGFR-3 phosphorylation without the activation of the receptor intrinsic kinase activity. Circ Res 2010; 106:1839-1848.
36. Xu Y, Yuan L, Mak J, et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol 2010; 188:115-130.
37. Liu P, Jenkins NA, Copeland NG. A highly effcient recom-bineering-based method for generating conditional knockout mutations. Genome Res 2003; 13:476-484.
38. Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci USA 1993; 90:8424-8428.
39. Farley FW, Soriano P, Steffen LS, Dymecki SM. Widespread recombinase expression using FLPeR (fipper) mice. Genesis 2000; 28:106-110.
40. Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular en-dothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61:1786-1790.
41. Baudin B, Bruneel A, Bosselut N, Vaubourdolle M. A protocol for isolation and culture of human umbilical vein endothe-lial cells. Nat Protocol 2007; 2:481-485.
42. Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single au-tophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001; 20:2768-2778.
43. Tammela T, He Y, Lyytikka J, et al. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. Circ Res 2007; 100:1468-1475.